Los Angeles, CA -- (ReleaseWire) -- 05/26/2009 -- BioMedReports, the news portal covering the biomedical news and financial sector takes a special look at which biotech firms could reap benefits from the just announced U.S. government's billion dollar initiative for the commercial-scale production of two potential vaccine ingredients for the pre-pandemic novel Influenza A(H1N1) stockpile.

The special report presents a comprehensive overview of influenza drugs and other antiviral agents that have made it to testing in humans and it also focuses on two companies who are taking advantage of this situation to showcase their technology: Philadelphia-based Hemispherx Biopharma Inc. (Amex: HEB) and Rockville, Md.-based Novavax Inc. (Nasdaq: NVAX).

The full report appears at BiomedReports.com.

http://biomedreports.com/articles/most-popular/1032-us-govt-takes-additional-steps-toward-development-of-takes-additional-steps-toward-development-of-vaccine-for-the-novel-influenza-a-h1n1.html

Biotech investors interested in seeing the complete database of clinical trials and upcoming FDA decisions can access that information here:

http://biomedreports.com/component/content/article/548.html

About BioMedReports.Com
BioMedReports.com is a news portal covering the biomedical news and financial sector. It features its own blog, discussion forum, stock research reports, news feeds, videos, press release capability, stock commentaries, and other unique content from the healthcare sector.

For more biomedical sector and investment news, go to www.BioMedReports.com

Disclosure: No positions.

Certain sections of this report contain forward-looking statements that are based on our reporters' expectations, estimates, projections and assumptions. Words such as "expects," "anticipates," "plans," "believes," "scheduled," "estimates" and variations of these words and similar expressions are intended to identify forward-looking statements, which include but are not limited to projections of revenues, earnings, segment performance, cash flows, contract awards, FDA announcements, trial and drug approvals, and company stability. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors including but not limited to the status or outcome of legal and/or regulatory proceedings.

All forward-looking statements speak only as of the date of this report or, in the case of any document incorporated by reference, the date of that document. All subsequent written and oral forward-looking statements attributable to the company or any person acting on the company's behalf are qualified by the cautionary statements in this section. BiomedReports.Com does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this report.